AACR 2021 roundup

In advance of AACR, Evaluate Vantage's Jacob Plieth spoke to the biotech investor Brad Loncar about the meeting's themes. 

Also check out our coverage of AACR 2021.

April 12

AACR 2021 – Pieris might have to bet on combinations

April 10

AACR 2021 – still awaiting validation, Sanofi keeps on buying

The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.

AACR 2021 – Affimed wins, Oncternal loses

Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.

March 26

Boehringer’s big cancer reveal draws near

The company might finally become an oncology player.

March 22

AACR 2021 preview – the early themes emerge

The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.